8-K: Senti Bio's SENTI-202 Shows Strong AML Trial Data, RMAT

Senti Biosciences announced positive initial Phase 1 clinical data for SENTI-202 in relapsed/refractory AML, achieving high response rates and a favorable safety profile, alongside an FDA RMAT designation.

Summary

• Initial clinical data from a Phase 1 trial of SENTI-202 for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML), has been announced.
• SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR NK) investigational cell therapy designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies while sparing healthy bone marrow cells.
• The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202.
• Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting.
• At the Recommended Phase 2 Dose (RP2D), 50% (6/12) of patients achieved an Overall Response Rate (ORR) and 42% (5/12) achieved a Complete Remission (CR) or CR with Partial Hematologic Recovery (CRh).
• Across all trial patients (9/18), 50% achieved an ORR and 39% (7/18) achieved a CR/CRh.
• 100% of all CRs and approximately 80%+ of all responses were Measurable Residual Disease (MRD) negative.
• The Kaplan-Meier estimate of median duration of composite Complete Remissions across all patients is 7.6 months (6.1, NE), with the longest durability of response greater than 1 year and continuing as of the data cut-off date.
• Pharmacodynamic data from patients validate SENTI-202's novel OR/NOT Logic Gate mechanism of action for selectively killing AML blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs).
• SENTI-202 continues to be well-tolerated, with no Dose-Limiting Toxicities (DLTs), no SENTI-202-related serious adverse events (SAEs), or adverse events resulting in discontinuation.
• Most frequent Grade 3+ Adverse Events (AEs) were predominantly hematologic, unrelated to SENTI-202, and consistent with events observed in R/R AML patients receiving lymphodepletion.
• Most frequent SENTI-202-related Adverse Events of Interest (AEI) were Grade 1/2 pyrexia, which resolved rapidly with standard of care treatment, supporting potential for outpatient delivery.
• SENTI-202 also received Orphan Drug Designation (ODD) in June 2025.

Sentiment

Score: 9

Explanation: The clinical data for SENTI-202 is highly positive, demonstrating strong efficacy (high ORR, CR/CRh, MRD-negative rates, durable responses) and a favorable safety profile in a challenging patient population. The FDA's RMAT and Orphan Drug designations further validate its potential. The company's plan for rapid advancement to pivotal studies and market expansion indicates significant future potential.

Positives

• Positive initial Phase 1 clinical data for SENTI-202 in relapsed/refractory AML, demonstrating high efficacy in a heavily pretreated patient population.
• FDA Regenerative Medicine Advanced Therapy (RMAT) designation granted, validating SENTI-202's potential to address a serious unmet medical need and potentially accelerating its development and review.
• Achieved a 50% Overall Response Rate (ORR) and 42% Complete Remission (CR)/CRh rates at the Recommended Phase 2 Dose (RP2D).
• Demonstrated 100% MRD-negative rates for all Complete Remissions and approximately 80%+ for all responses, indicating deep and durable remissions.
• Estimated median duration of composite Complete Remissions across all patients is 7.6 months, with the longest response exceeding 1 year.
• Favorable safety profile with no Dose-Limiting Toxicities (DLTs) or SENTI-202-related serious adverse events (SAEs), supporting the potential for outpatient delivery.
• Pharmacodynamic data validate the Logic Gate mechanism of action, confirming selective killing of AML blasts and leukemic stem cells while sparing healthy hematopoietic stem and progenitor cells.
• Orphan Drug Designation (ODD) was received in June 2025, providing incentives for development.
• The data supports rapid advancement of SENTI-202 into pivotal studies and potential expansion into other indications like newly diagnosed AML, pediatric AML, and myelodysplastic syndromes (MDS).
• Management believes SENTI-202 has a multi-billion dollar market potential due to CD33 and/or FLT3 expression in most AML patients.

Negatives

• The patient population studied was heavily pretreated, with many having adverse risk genetics and being refractory to prior regimens, indicating the severity and challenge of the disease.
• Most frequent Grade 3+ Adverse Events (AEs) were predominantly hematologic, consistent with lymphodepletion, although assessed as unrelated to SENTI-202.
• A preliminary trend to increased SENTI-202 exposure in responders and with increased dose level was observed, but it was noted as 'statistically not-significant'.

Risks

• Uncertainty in the timing or results of clinical studies, patient enrollment, and GMP manufacturing startup activities.
• The ability of any product candidate to perform in humans in a manner consistent with nonclinical, preclinical, or previous clinical study data.
• Dependence on third parties in connection with clinical studies and GMP manufacturing activities.
• Risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation, and rising interest rates on business operations.
• Risks related to the timing and utilization of any grants, such as from CIRM.
• Product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects.
• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, and changes in laws and regulations affecting the business.
• The ability to implement business plans, forecasts, and other expectations.
• The risk of downturns and a changing regulatory landscape in the highly competitive industry.
• Risks relating to the uncertainty of any projected financial information.
• The ability to obtain, maintain, and protect intellectual property.
• The ability to manage expenses and to obtain additional funding when needed to support business activities and establish and maintain strategic business alliances and new business initiatives.

Future Outlook

The company plans to rapidly advance SENTI-202 into pivotal studies for relapsed/refractory AML and explore its potential in broader patient populations, including newly diagnosed AML, pediatric AML, and myelodysplastic syndromes (MDS) starting in 2026. They also intend to expand their validated Logic Gate technology into other modalities, such as T cells and in vivo CARs, for additional cancer indications.

Management Comments

• "SENTI-202 continues to demonstrate deep, durable responses and a favorable safety profile in patients with relapsed or refractory AML, where standard therapies often offer patients a survival rate of just a few months." Dr. Nosha Farhadfar, Hematologist & Adult Bone Marrow Transplant Specialist.
• "I'm looking forward to continuing to participate in this clinical evaluation to further investigate SENTI-202's efficacy and safety in patients with R/R AML, with the ambitious and exciting goal of selectively targeting AML blasts and LSCs while protecting healthy HSPCs." Dr. Nosha Farhadfar.
• "Existing cell therapies and biologic drugs have generally been limited to a subset of indications that have cancer-specific targets due to difficulty in killing cancer aggressively without triggering dangerous attacks on healthy tissues." Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences.
• "To overcome this longstanding key challenge, our Logic Gated cell therapies recognize and kill cancer cells based on multiple targets while simultaneously protecting healthy cells from toxicity." Timothy Lu, MD, PhD.
• "Since CD33 and/or FLT3 are expressed in most AML patients, we believe that SENTI-202 has a multi-billion dollar market potential." Timothy Lu, MD, PhD.
• "Moreover, our positive SENTI-202 data further validates the potential for Senti Bio's platform to transform the treatment of a broad set of cancers where other medicines have insufficient therapeutic windows." Timothy Lu, MD, PhD.
• "This clinical evidence, together with the receipt of recent RMAT and Orphan Drug Designations from the FDA, allows us to rapidly advance SENTI-202 into pivotal studies and to explore its potential in broader patient populations that may include newly diagnosed AML, pediatric AML, and myelodysplastic syndromes (MDS)." Kanya Rajangam, M.D., Ph.D., Chief Medical Officer at Senti Bio.

Industry Context

The announcement positions SENTI-202 as a significant advancement in the treatment of relapsed/refractory Acute Myeloid Leukemia (AML), a disease characterized by high unmet medical need and poor patient prognosis with existing therapies. The Logic Gate mechanism represents a novel approach in cell therapy, aiming to overcome the challenge of off-target toxicity by selectively targeting cancer cells while sparing healthy tissues. This innovation could broaden the applicability of CAR-NK therapies and potentially set a new standard for precision in oncology. The FDA's RMAT designation underscores the therapy's potential to offer substantial improvement over available treatments for a serious condition, aligning with broader industry trends towards more targeted and less toxic cancer therapies.

Comparison to Industry Standards

• Current standard of care for relapsed/refractory AML typically yields Complete Remission (CR) rates of approximately 12-25% and CR/CRh rates of 20-35%, with a median overall survival (OS) of around 5.3 months. SENTI-202 demonstrated a 42% CR/CRh rate at the Recommended Phase 2 Dose (RP2D) and a median duration of composite CR of 7.6 months, suggesting superior efficacy and durability compared to existing treatments.
• SENTI-202 achieved 100% MRD-negative rates for all Complete Remissions, which is a critical indicator of deep remission and improved long-term outcomes, often a challenge for conventional AML therapies.
• Existing cell therapies and biologic drugs are frequently limited by off-target toxicity. SENTI-202's Logic Gate mechanism, which selectively kills AML blasts and leukemic stem cells while sparing healthy hematopoietic stem and progenitor cells (HSPCs), aims to provide a wider therapeutic window and a more favorable safety profile compared to non-Logic Gate approaches.
• The favorable safety profile of SENTI-202, with no Dose-Limiting Toxicities or related serious adverse events and predominantly Grade 1/2 pyrexia as the most frequent related AEI, contrasts with the significant myelotoxicity and other vital organ toxicities often associated with current intensive chemotherapy regimens for AML.

Stakeholder Impact

• Shareholders: Potential for significant positive impact due to strong clinical data, RMAT designation, and the prospect of rapid advancement into pivotal studies and a multi-billion dollar market opportunity, which could lead to increased share price.
• Patients with R/R AML: Significant positive impact by offering a novel, potentially more effective, and safer treatment option for a disease with very poor prognosis and limited existing therapies.
• Employees: Positive impact through continued development, potential for company growth, and validation of the company's proprietary Gene Circuit platform.
• Healthcare Providers: Provides a promising new therapeutic tool for managing relapsed/refractory AML, potentially improving patient outcomes and expanding treatment options.

Next Steps

• Launch pivotal trial for relapsed/refractory AML.
• Expand into other indications, such as newly diagnosed AML, pediatric AML, and myelodysplastic syndromes (MDS) in 2026.
• Continue SENTI-202 manufacturing.
• Undertake pivotal SENTI-202 process development.
• Initiate pivotal SENTI-202 manufacturing.
• Engage in FDA interaction on pivotal study plans.
• Seek additional financing to continue pivotal process development (end of 2025) and support enrollment of dose expansion patients (2026).
• Expand validated Logic Gate technology into other modalities (e.g., T cells, in vivo CARs) for additional cancers.

Key Dates

Recommendation

The clinical data for SENTI-202 in relapsed/refractory AML is exceptionally strong, demonstrating high response rates (50% ORR, 42% CR/CRh at RP2D), deep remissions (100% MRD-negative CRs), and durable responses (median 7.6 months) in a heavily pretreated patient population where standard therapies offer limited survival. The favorable safety profile, with no DLTs or related SAEs, and the potential for outpatient administration are significant advantages. The FDA's Regenerative Medicine Advanced Therapy (RMAT) designation accelerates development and regulatory review, highlighting the drug's potential to address a serious unmet medical need. This, combined with Orphan Drug Designation and a projected multi-billion dollar market opportunity, positions SENTI-202 as a potential best-in-class therapy. The company's plan to rapidly advance to pivotal studies and expand into other AML/MDS indications further de-risks the asset and suggests substantial upside. While future financing is noted as a requirement, the strong clinical validation and regulatory support make this a compelling investment opportunity.

Keywords

Senti Biosciences, SNTI, SENTI-202, CAR NK cell therapy, Acute Myeloid Leukemia, AML, Relapsed/Refractory, R/R AML, Logic Gate, CD33, FLT3, EMCN, Phase 1 clinical trial, Clinical data, FDA RMAT designation, Orphan Drug Designation, Hematologic malignancies, Cell therapy, Biotechnology, Oncology, Gene Circuit platform, ASH 2025